Detail akcie NervGn Rg-S-144A-AI online

Business Summary: NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, NervGen Pharma Corp revenues was not reported. Net loss increased 11% to C$17.2M. Higher net loss reflects Salaries and benefits increase of 54% to C$2.5M (expense), Chemistry, manufacturing and controls increase of 65% to C$1.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.23 to -C$0.24.